Levetiracetam Tablet, Film Coated
Product Images NDC 70518-1108

10 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-1108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (24fe2e98 0b9f 4eea A745 E26002329cec 01)

Figure 1 (24fe2e98 0b9f 4eea A745 E26002329cec 01)
A formula illustrating the calculation of total daily dose (mL/day) for a medication based on the daily dose in mg/kg/day multiplied by patient weight in kg, divided by a concentration of 100 mg/mL.*
FDA Label Image

Figure 2 (24fe2e98 0b9f 4eea A745 E26002329cec 02)

Figure 2 (24fe2e98 0b9f 4eea A745 E26002329cec 02)
This text panel shows equations used to calculate creatinine clearance (CLcr). The formula includes factors such as patient age, weight, serum creatinine, gender adjustment for females, and an adjustment for body surface area (BSA), providing a method for individualized CLcr estimation in mL/min.*
FDA Label Image

Structure (24fe2e98 0b9f 4eea A745 E26002329cec 03)

Structure (24fe2e98 0b9f 4eea A745 E26002329cec 03)
Chemical structure diagram of levetiracetam, showing its molecular configuration including a pyrrolidone ring, amide group, and side chains consistent with the generic drug levetiracetam.*
FDA Label Image

Figure 4 (24fe2e98 0b9f 4eea A745 E26002329cec 04)

Figure 4 (24fe2e98 0b9f 4eea A745 E26002329cec 04)
A vertical bar chart compares the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis shows the percentage of patients from 0% to 45%. The Placebo group (N=95) has about 7.4%, Levetiracetam 1000 mg/day (N=97) about 37.1%, and Levetiracetam 3000 mg/day (N=101) about 39.6%, with asterisks indicating statistical significance for the Levetiracetam groups.*
FDA Label Image

Figure 5 (24fe2e98 0b9f 4eea A745 E26002329cec 05)

Figure 5 (24fe2e98 0b9f 4eea A745 E26002329cec 05)
Bar chart depicting the percentage of patients across three groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%). The chart visually compares patient response rates for varying doses of Levetiracetam versus placebo.*
FDA Label Image

Figure 6 (24fe2e98 0b9f 4eea A745 E26002329cec 06)

Figure 6 (24fe2e98 0b9f 4eea A745 E26002329cec 06)
A bar graph comparing the percentage of patients achieving a certain outcome between a placebo group (14.4%) and a Levetiracetam 3000 mg/day group (39.4%). The vertical axis represents the percentage of patients, and sample sizes are noted below each group label.*
FDA Label Image

Figure 7 (24fe2e98 0b9f 4eea A745 E26002329cec 07)

Figure 7 (24fe2e98 0b9f 4eea A745 E26002329cec 07)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The vertical axis shows the percentage of patients from 0% to 45%. The placebo group (N=97) has a bar reaching 19.6%, while the Levetiracetam group (N=101) has a bar reaching 44.6% with an asterisk above it.*
FDA Label Image

Figure 8 (24fe2e98 0b9f 4eea A745 E26002329cec 08)

Figure 8 (24fe2e98 0b9f 4eea A745 E26002329cec 08)
A bar graph comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The y-axis represents the percentage of patients, ranging from 0% to 45%. The Placebo group shows 19.6%, while the Levetiracetam group shows 43.1%. An asterisk is displayed on the Levetiracetam bar, indicating statistical significance or emphasis.*
FDA Label Image

Figure 9 (24fe2e98 0b9f 4eea A745 E26002329cec 09)

Figure 9 (24fe2e98 0b9f 4eea A745 E26002329cec 09)
A bar chart comparing the percentage of patients between two groups: Placebo (N=84) with 45.2%, and Levetiracetam (N=79) with 72.2%. The chart's vertical axis shows patient percentage from 0% to 100%.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Levetiracetam 500 mg film-coated tablets packaging label shows the product name with highlighted strength and dosage form. The label indicates a quantity of 30 tablets, is marked RX only, and includes NDC 70518-1108-00. The manufacturer listed is Lupin Pharma, Baltimore, MD, with repackaging by RemedyRepack Inc., Indiana, PA. Storage instructions and a QR code are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.